US LNG exports surge but will buyers in China turn up?
Investing.com - Jefferies raised its price target on Insmed (NASDAQ:INSM) to $129.00 from $123.00 while maintaining a Buy rating on the stock. The company’s shares, currently trading at $109.34, have delivered an impressive 56.7% return over the past year and are trading near their 52-week high of $113.10. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $108 to $135.
The firm cited the upcoming Prescription Drug User Fee Act (PDUFA) date for Insmed’s brensocatib treatment for bronchiectasis, scheduled for August 12, 2025. Jefferies expects Insmed to secure this first-in-disease approval.
The anticipated label will likely cover bronchiectasis patients with two or more annual exacerbations, which aligns with payer expectations. Phase 2 data for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) is expected by year-end.
Jefferies views Insmed as a commercial story with a proven record of late-stage success and a diversified portfolio. This portfolio includes TPIP for pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD).
The company’s pipeline also features brensocatib in hidradenitis suppurativa (HS), with Phase 2 futility results expected in Q1 2026, and INS1201, a gene therapy for Duchenne muscular dystrophy (DMD).
In other recent news, Insmed Inc. reported its second-quarter 2025 earnings, highlighting a revenue beat but a larger-than-expected loss per share. The company achieved a revenue of $107.4 million, surpassing the forecasted $103.41 million. However, the earnings per share (EPS) were reported at a negative $1.70, which was below the expected negative $1.30. Despite the revenue success, the earnings miss contributed to a decline in the stock’s pre-market trading. No analyst upgrades or downgrades were mentioned in the context provided. These developments are part of Insmed’s ongoing financial reporting. Investors may want to keep an eye on further announcements from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.